N. Shah

Oncology · The Lancet · 2013–2019

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom N. Shah trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. June
  2. B. Levine

Papers from N. Shah's perspective

Ordered by how strongly the researchers N. Shah trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate… (Journal of Clinical Oncology)
  2. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (The Lancet Oncology)
  3. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo (Molecular Therapy)
  4. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (New England Journal of Medicine)
  5. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. (Blood)
  6. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
  7. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
  8. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
  9. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (New England Journal of Medicine)
  10. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (Science Translational Medicine)

Their papers